Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|2|179-179

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.2, 2015-02, pp. : 179-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3612-3621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 967-969

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-06 ,pp. : 534-541

Karger

Access to resources Recommend Favorite

“Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 375-382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 105-109

Karger

Access to resources Recommend Favorite